HRS-5965

富马酸立康可泮

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameHRS-5965
Drug Alias NameHRS-5965HRS5965
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsHemoglobinuria, ParoxysmalAnemia, Hemolytic, AutoimmuneAnemia, Hemolytic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesChengdu Suncadia Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Suncadia Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalAnemia, Hemolytic, AutoimmuneAnemia, Hemolytic +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A